Model-Based Quantification of Glucagon-Like Peptide-1-Induced Potentiation of Insulin Secretion in Response to a Mixed Meal Challenge

Diabetes Technology and Therapeutics

Volumn 18, Issue 1, 2016, Pages 39-46

  Dalla Man, Chiara ^a   Micheletto, Francesco ^a   Sathananthan, Matheni ^b   Vella, Adrian ^b   Cobelli, Claudio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BODY MASS; CELL FUNCTION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; TEST MEAL; BLOOD; EATING; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INTOLERANCE; MEAL; METABOLISM; MIDDLE AGED; NORMAL HUMAN; PHYSIOLOGY; SECRETION (PROCESS); STATISTICAL MODEL;

BLOOD GLUCOSE; C-PEPTIDE; EATING; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INTOLERANCE; HEALTHY VOLUNTEERS; HUMANS; INSULIN; INSULIN-SECRETING CELLS; LINEAR MODELS; MEALS; MIDDLE AGED;

EID: 84954429527     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2015.0146     Document Type: Article

References (25)

1. Baggio LL, Drucker DJ: Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-2157.
2. Drucker DJ, Nauck MA: The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705.
3. Nauck MA, Meier JJ: Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 2005;128: 135-148.
4. Holst JJ, Toft-Nielsen MB, Orskov C, et al.: On the effects of glucagon-like peptide-1 on blood glucose regulation in normal and diabetic subjects. Ann N Y Acad Sci 1996;805: 729-736.
5. Kieffer TJ, Habener JF: The glucagon-like peptides. Endocr Rev 1999;20:876-913.
6. Vahl T, D'Alessio D: Enteroinsular signaling: perspectives on the role of the gastrointestinal hormones glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide in normal and abnormal glucose metabolism. Curr Opin Clin Nutr Metab Care 2003;6:461-468.
7. Dalla Man C, Bock G, Giesler PD, et al.: Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes. Diabetes Care 2009;32:14-18.
8. Mari A, Schmitz O, Gastaldelli A, et al.: Meal and oral glucose tests for assessment of beta-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 2002;283:E1159-E1166.
9. Campioni M, Toffolo G, Shuster LT, et al.: Incretin effect potentiates beta-cell responsivity to glucose as well as to its rate of change: OGTT and matched intravenous study. Am J Physiol Endocrinol Metab 2007;292:E54-E60.
10. Toffolo G, Breda E, Cavaghan MK, et al.: Quantitative indexes of beta-cell function during graded up&down glucose infusion from C-peptide minimal models. Am J Physiol Endocrinol Metab 2001;280:E2-E10.
11. Tura A, Muscelli E, Gastaldelli A, et al.: Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic. Diabetologia 2014;57:1199-1203.
12. Dalla Man C, Micheletto F, Sathananthan A, et al.: A model of GLP-1 action on insulin secretion in nondiabetic subjects. Am J Physiol Endocrinol Metab 2010;298:E1115-E1121.
13. Bergman RN, Phillips LS, Cobelli C: Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 1981;68:1456-1467.
14. Cobelli C, Toffolo GM, Dalla Man C, et al.: Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am J Physiol Endocrinol Metab 2007; 293:E1-E15.
15. Denti P, Toffolo G, Cobelli C: The disposition index: from individual to population approach. Am J Physiol 2012;303: E576-E586.
16. Bock G, Dalla Man C, Campioni M, et al.: Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 2006;55:3536-3549.
17. Bock G, Dalla Man C, Micheletto F, et al.: The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clin Endocrinol (Oxf) 2010;73:189-196.
18. Breda E, Cavaghan MK, Toffolo G, et al.: Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. Diabetes 2001;50:150-158.
19. Eaton RP, Allen RC, Schade DS, et al.: Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. J Clin Endocrinol Metab 1980;51:520-528.
20. Van Cauter E, Mestrez F, Sturis J, et al.: Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992;41:368-377.
21. Carson E, Cobelli C: Modeling Methodology for Physiology and Medicine, 2nd ed. London: Elsevier, 2014.
22. Toffolo G, Campioni M, Basu R, et al.: A minimal model of insulin secretion and kinetics to assess hepatic insulin extraction. Am J Physiol Endocrinol Metab 2006;290: E169-E176.
23. Estall JL, Drucker DJ: Glucagon and glucagon-like peptide receptors as drug targets. Curr Pharm Des 2006;12:1731-1750.
24. Kieffer TJ: Gastro-intestinal hormones GIP and GLP-1. Ann Endocrinol (Paris) 2004;65:13-21.
25. Chen M, Bergman RN, Pacini G, Porte D Jr: Pathogenesis of age-related glucose intolerance in man: insulin resistance and decreased beta-cell function. J Clin Endocrinol Metab 1985;60:13-20.